

Ref No.: ZLL/CS/BM/BSE-NSE

Date: 12.11.2025

BSE Limited, Compliance Department, P. J. Towers, Dalal Street, Mumbai – 400 001 (Scrip Code - 541400)	National Stock Exchange of India Limited, Listing Compliance Department, Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051 (Symbol - ZIMLAB)
--	---

Dear Sir,

Sub : Outcome of Board Meeting held on 12.11.2025

Ref : Intimation of Board Meeting dt. 05.11.2025

In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today has inter-alia considered and approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half ended 30th September, 2025.

Copy of the Unaudited Financial Results (Consolidated and Standalone) for the quarter and half ended 30th September, 2025 along with the Limited Review Report issued by Deloitte Haskins & Sells LLP, Statutory Auditors of the Company is enclosed herewith.

Kindly take the intimation on record.

The Board Meeting commenced at 10:00 a.m. (IST) and concluded at 06:30 p.m. (IST)

Thanking you,

Yours faithfully,
For ZIM LABORATORIES LIMITED

(Piyush Nikhade)
Company Secretary and Compliance Officer
Membership No. A38972

Encl: as above

ZIM LABORATORIES LIMITED

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ZIM LABORATORIES LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **ZIM LABORATORIES LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and half year ended September 30, 2025 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement includes the results of the following entities:

Name of the Company	Relationship
ZIM Laboratories Limited, India	Parent Company
ZIM Laboratories FZE, Sharjah	Subsidiary Company
ZIM Health Technologies Limited, India	Subsidiary Company
SIA ZIM Laboratories Limited, Latvia	Subsidiary Company
ZIM Thinorals Private Limited, India	Subsidiary Company
ZIMTAS PTY Limited, Australia	Subsidiary Company
ZIM Laboratories Middle East DMCC, Dubai	Step-Down Subsidiary
ZIM Scientific Office LLC, Dubai	Step-Down Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Deloitte
Haskins & Sells LLP**

6. The consolidated financial results of the Company for the quarter and half year ended September 30, 2024 and year ended March 31, 2025 included in the Statement, were reviewed/ audited by another auditor who expressed an unmodified conclusion/ opinion on those statements on November 9, 2024 for the quarter and half year ended September 30, 2024 and May 20, 2025 for the year ended March 31, 2025.

Our conclusion on the statement is not modified in respect of this matter.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

Viral
Rajnikant
Shah



Digitally signed by
Viral Rajnikant Shah
Date: 2025.11.12
15:23:10 +05'30'

Viral R. Shah
Partner
(Membership No. 117654)
(UDIN: 25117654BMLLPP5085)

Place: Mumbai
Date: November 12, 2025

RB



ZIM Laboratories Limited

Registered Office : Sadoday Gyan(Ground Floor),Opp.NADT,Nelson Square Nagpur - 440013, Maharashtra, India

CIN:L99999MH1984PLC032172, Website: www.zimlab.in

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2025

(Rs. in lakhs, unless otherwise stated)

Sr. No.	Particulars	Quarter ended			Half Year ended		Year ended
		30 September 2025	30 June 2025	30 September 2024	30 September 2025	30 September 2024	31 March 2025
		(Unaudited)	(Unaudited)	(Unaudited) Refer Note 3	(Unaudited)	(Unaudited) Refer Note 3	(Audited) Refer Note 3
1	Income						
	a) Revenue from operations	8,871.13	7,175.61	9,214.33	16,046.74	17,396.77	37,903.10
	b) Other income	204.30	147.63	132.08	351.93	231.97	578.41
	Total income	9,075.43	7,323.24	9,346.41	16,398.67	17,628.74	38,481.51
2	Expenses						
	a) Cost of materials consumed	4,349.90	2,761.73	3,551.84	7,111.63	6,652.77	15,500.40
	b) Purchases of stock-in-trade	292.89	159.30	313.84	452.19	579.58	1,157.82
	c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(678.38)	79.86	345.17	(598.52)	601.57	126.65
	d) Employee benefits expenses	1,631.99	1,461.27	1,545.13	3,093.26	2,996.05	6,075.98
	e) Finance costs	315.94	330.35	288.75	646.29	574.60	1,138.82
	f) Depreciation and amortisation	498.03	486.35	500.09	984.38	994.37	2,011.34
	g) Other expenses	2,699.44	2,287.58	2,505.30	4,987.02	4,810.07	10,669.56
	Total expenses	9,109.81	7,566.44	9,050.12	16,676.25	17,209.01	36,680.57
3	Profit/(loss) before tax (1-2)	(34.38)	(243.20)	296.29	(277.58)	419.73	1,800.94
4	Tax expense/(credit)						
	Current Tax	2.10	8.72	24.70	10.82	52.32	467.41
	Deferred Tax	5.98	(64.43)	33.45	(58.45)	39.44	117.03
	Total tax expense/(credit)	8.08	(55.71)	58.15	(47.63)	91.76	584.44
5	Profit/(loss) after tax (3-4)	(42.46)	(187.49)	238.14	(229.95)	327.97	1,216.50
6	Other comprehensive income - profit/(loss)						
	a) Items that will not be reclassified to profit or loss	(18.99)	(18.99)	(13.47)	(37.98)	(26.94)	(75.95)
	b) Tax (expense)/credit on the items that will not be reclassified to profit or loss	5.53	5.53	3.92	11.06	7.84	22.11
	c) Items that may be reclassified to profit or loss	45.94	55.35	24.84	101.29	27.34	51.09
	d) Tax (expense)/credit on the items that will be reclassified to profit or loss	-	-	-	-	-	-
	Other comprehensive income (net of tax) - profit/(loss)	32.48	41.89	15.29	74.37	8.24	(2.75)
7	Total comprehensive income (5+6)	(9.98)	(145.60)	253.43	(155.58)	336.21	1,213.75
8	Net Profit/(loss) after tax attributable to						
	Owners	(42.46)	(187.49)	238.14	(229.95)	327.97	1,216.52
	Non-controlling interest	(0.00)	-	-	(0.00)	(0.00)	(0.02)
9	Other comprehensive Income attributable to						
	Owners	32.48	41.89	15.29	74.37	8.24	(2.75)
	Non-controlling interest	-	-	-	-	-	-
10	Total Comprehensive Income attributable to						
	Owners	(9.98)	(145.60)	253.43	(155.58)	336.21	1,213.77
	Non-controlling interest	(0.00)	-	-	(0.00)	(0.00)	(0.02)
11	Paid-up equity share capital (face value of Rs. 10/- each)	4,873.58	4,872.58	4,872.58	4,873.58	4,872.58	4,872.58
12	Other equity (revaluation reserve : Rs. Nil)	-	-	-	-	-	20,351.17
13	Earnings per share (face value of Rs. 10/- each) (not annualised) (Rs.)						
	Basic	(0.09)	(0.38)	0.49	(0.47)	0.67	2.50
	Diluted	(0.09)	(0.38)	0.49	(0.47)	0.67	2.50

RB

Consolidated Balance Sheet

	As at 30 September 2025 Rs. in lakhs (Unaudited)	As at 31 March 2025 Rs. in lakhs (Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	15,128.93	15,834.39
Capital work-in-progress	4,599.55	4,405.44
Goodwill on consolidation	16.94	16.94
Other intangible assets	576.86	576.33
Intangible assets under development	3,014.21	2,641.05
Financial Assets		
Investments	5.00	5.00
Other financial assets	79.79	103.27
Income tax assets (net)	137.62	103.82
Other non-current assets	772.95	385.36
	24,331.85	24,071.60
Current assets		
Inventories	9,558.65	8,647.00
Financial Assets		
Trade receivables	10,208.35	10,692.03
Cash and cash equivalents	390.50	194.66
Bank balances other than cash and cash equivalents	72.48	54.59
Other financial assets	38.18	30.67
Other current assets	2,121.20	3,511.79
	22,389.36	23,130.74
Assets held for sale (Refer Note 4)	293.02	-
TOTAL ASSETS	47,014.23	47,202.34
EQUITY AND LIABILITIES		
Equity		
Equity share capital	4,873.58	4,872.58
Other equity	20,259.75	20,351.17
Equity attributable to equity holders of the parent	25,133.33	25,223.75
Non controlling interest	0.05	0.05
Total equity	25,133.38	25,223.80
Liabilities		
Non-current liabilities		
Financial Liabilities		
Borrowings	4,672.39	4,030.10
Other financial liabilities	146.84	206.97
Deferred tax liabilities (net)	1,035.50	1,105.01
	5,854.73	5,342.08
Current liabilities		
Financial Liabilities		
Borrowings	7,058.06	7,186.45
Lease Liabilities	417.57	356.43
Trade payables		
-total outstanding due of micro enterprises and small enterprises	402.30	668.46
-total outstanding due of creditors other than micro enterprises and small enterprises	5,756.24	6,282.12
Other financial liabilities	1,045.75	1,170.36
Other current liabilities	1,207.55	612.70
Provisions	53.11	67.90
Current Tax Liabilities (net)	85.54	292.04
	16,026.12	16,636.46
TOTAL LIABILITIES	21,880.85	21,978.54
TOTAL EQUITY AND LIABILITIES	47,014.23	47,202.34

Consolidated Statement of Cash Flow

	Half Year ended 30 September 2025 Rs. in lakhs (Unaudited)	Half Year ended 30 September 2024 Rs. in lakhs (Unaudited)
Cash flow from operating activities		
Profit before tax	(277.58)	419.73
Depreciation and amortisation	984.38	994.37
Interest on lease deposits	(5.80)	(3.61)
Gain on sale of property, plant and equipment (net)	(17.26)	(3.01)
Unrealized foreign exchange gain (net)	(173.31)	(78.40)
Dividend income on investments	(0.75)	(0.75)
Interest income	(12.88)	(2.11)
Share based payments to employees	57.40	65.39
Loss allowance - trade receivables	51.52	-
Finance costs	646.29	574.60
Others	-	(5.12)
Operating profit before working capital changes	1,252.01	1,961.09
Movement in working capital :		
Increase in trade & other payables and provisions	(120.57)	(1,443.22)
(Increase)/decrease in inventories	(911.65)	1,333.71
Decrease in trade and other receivables	2,023.09	1,857.58
Net Cash generated from operations	2,242.88	3,709.16
Direct taxes paid (net of refunds)	(251.12)	(28.98)
Net cash from operating activities (A)	1,991.76	3,680.18
Cash flow from investing activities		
Purchases of property, plant and equipment and intangibles assets (Refer Note i)	(1,587.29)	(2,459.70)
Sale proceeds of property, plant and equipment	28.48	3.72
Deposits placed with bank (having original maturity of more than three months)	-	(34.50)
Maturity of bank deposits (having original maturity of more than three months)	-	17.50
Interest received	1.10	0.40
Dividend received	0.75	0.75
Net cash used in investing activities (B)	(1,556.96)	(2,471.83)
Cash flow from financing activities		
Proceeds from issue of equity share	7.76	-
Proceeds from long term borrowings	1,690.04	1,403.86
Repayment of long term borrowings	(1,001.86)	(690.04)
Repayment of short term borrowings (net)	(197.58)	(1,545.32)
Repayment of principal portion of lease obligations	(186.97)	(189.94)
Finance costs paid	(653.24)	(644.25)
Changes in unclaimed dividend bank balances	0.14	0.04
Changes in unclaimed dividend liabilities	(0.14)	(0.04)
Net cash generated used in financing activities (C)	(341.85)	(1,665.69)
Effects of exchange rate changes on cash and cash equivalents (D)	102.89	4.82
Net increase in cash and cash equivalents (A+B+C+D)	195.84	(452.52)
Opening cash and cash equivalents	194.66	960.02
Closing cash and cash equivalents	390.50	507.50
Components of cash and cash equivalents		
Cash on hand	3.40	16.26
Balances with banks in:		
- Current accounts	387.10	491.24
Total Cash and cash equivalents	390.50	507.50

Note (i) Includes capital work-in-progress, capital advance, payables for property, plant and equipment, intangibles assets and intangible assets under development.

Note (ii) The Statement of Cash Flow has been prepared under the indirect method as set out in Indian Accounting Standard (Ind AS 7) Statement of Cash flows.

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ZIM LABORATORIES LIMITED

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **ZIM LABORATORIES LIMITED** ("the Company"), for the quarter and half year ended September 30, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The standalone financial results of the Company for the quarter and half year ended September 30, 2024 and year ended March 31, 2025 included in the Statement, were reviewed/ audited by another auditor who expressed an unmodified conclusion/ opinion on those statements on November 9, 2024 for the quarter and half year ended September 30, 2024 and May 20, 2025 for the year ended March 31, 2025.

Our conclusion on the statement is not modified in respect of this matter.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

Viral
Rajnikant
Shah

Digitally signed by
Viral Rajnikant Shah
Date: 2025.11.12
15:22:22 +05'30'

Viral R. Shah
Partner
(Membership No. 117654)
(UDIN: 25117654BMLLP04973)

Place: Mumbai
Date: November 12, 2025



ZIM Laboratories Limited

Registered Office : Sadoday Gyan(Ground Floor),Opp.NADT,Nelson Square Nagpur - 440013, Maharashtra, India
CIN:L99999MH1984PLC032172, Website: www.zimlab.in

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2025

(Rs. in lakhs, unless otherwise stated)

Sr. No.	Particulars	Quarter ended			Half Year ended		Year ended
		30 September 2025 (Unaudited)	30 June 2025 (Unaudited)	30 September 2024 (Unaudited) Refer Note 3	30 September 2025 (Unaudited)	30 September 2024 (Unaudited) Refer Note 3	31 March 2025 (Audited) Refer Note 3
1	Income						
	a) Revenue from operations	8,839.43	7,142.77	8,972.13	15,982.20	17,172.54	37,563.55
	b) Other income	204.39	147.56	132.15	351.95	230.18	562.09
	Total income	9,043.82	7,290.33	9,104.28	16,334.15	17,402.72	38,125.64
2	Expenses						
	a) Cost of materials consumed	4,349.90	2,761.73	3,551.84	7,111.63	6,652.77	15,500.40
	b) Purchases of stock-in-trade	292.89	159.30	313.84	452.19	579.58	1,157.82
	c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(678.38)	79.86	287.20	(598.52)	601.57	126.65
	d) Employee benefits expenses	1,546.06	1,357.42	1,443.76	2,903.48	2,791.81	5,640.62
	e) Finance costs	315.94	330.35	288.61	646.29	574.36	1,138.58
	f) Depreciation and amortisation	482.83	478.98	497.34	961.81	988.94	1,989.14
	g) Other expenses	2,711.77	2,350.98	2,536.53	5,062.75	4,920.11	10,811.22
	Total expenses	9,021.01	7,518.62	8,919.12	16,539.63	17,109.14	36,364.43
3	Profit/(loss) before tax (1-2)	22.81	(228.29)	185.16	(205.48)	293.58	1,761.21
4	Tax expense/(credit)						
	Current Tax	-	-	23.62	-	44.62	444.69
	Deferred Tax	11.21	(59.10)	39.97	(47.89)	51.49	142.12
	Total tax expense/(credit)	11.21	(59.10)	63.59	(47.89)	96.11	586.81
5	Profit/(loss) after tax (3-4)	11.60	(169.19)	121.57	(157.59)	197.47	1,174.40
6	Other comprehensive income - profit/(loss)						
	a) Items that will not be reclassified to profit or loss	(18.99)	(18.99)	(13.47)	(37.98)	(26.94)	(75.95)
	b) Tax (expense)/credit on the items that will not be reclassified to profit or loss	5.53	5.53	3.92	11.06	7.84	22.11
	Other comprehensive income (net of tax) - profit/(loss)	(13.46)	(13.46)	(9.55)	(26.92)	(19.10)	(53.84)
7	Total comprehensive income (5+6)	(1.86)	(182.65)	112.02	(184.51)	178.37	1,120.56
8	Paid-up equity share capital (face value of Rs. 10/- each)	4,873.58	4,872.58	4,872.58	4,873.58	4,872.58	4,872.58
9	Other equity (revaluation reserve : Rs. Nil)						19,578.80
10	Earnings per share (face value of Rs. 10/- each) (not annualised) (Rs.)						
	Basic	0.03	(0.35)	0.25	(0.32)	0.41	2.41
	Diluted	0.03	(0.35)	0.25	(0.32)	0.41	2.41

RB

Standalone Balance Sheet

	As at 30 September 2025 Rs. in lakhs (Unaudited)	As at 31 March 2025 Rs. in lakhs (Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	15,122.94	15,828.14
Capital work-in-progress	4,599.55	4,405.44
Intangible assets	419.51	531.39
Intangible assets under development	2,523.52	2,161.15
Financial Assets		
Investment in subsidiaries	1,631.34	1,298.90
Other Investments	5.00	5.00
Other financial assets	78.67	102.18
Income tax assets (net)	120.02	86.25
Other non-current assets	772.95	385.36
	25,273.50	24,803.81
Current assets		
Inventories	9,558.65	8,647.00
Financial Assets		
Trade receivables	8,930.70	9,368.06
Cash and cash equivalents	17.70	36.36
Bank balances other than cash and cash equivalents	63.47	45.59
Other financial assets	38.18	30.67
Other current assets	2,027.45	3,507.03
	20,636.15	21,634.71
Assets held for sale (Refer Note 4)	293.02	-
TOTAL ASSETS	46,202.67	46,438.52
EQUITY AND LIABILITIES		
Tax expense/(credit)		
Equity share capital	4,873.58	4,872.58
Other equity	19,458.44	19,578.80
	24,332.02	24,451.38
Liabilities		
Non-current liabilities		
Financial Liabilities		
Borrowings	4,672.39	4,030.10
Lease Liabilities	146.84	206.97
Deferred tax liabilities (net)	1,071.15	1,130.10
	5,890.38	5,367.17
Current liabilities		
Financial Liabilities		
Borrowings	7,058.06	7,186.45
Lease Liabilities	417.57	356.43
Trade payables		
-total outstanding due of micro enterprises and small enterprises	402.30	668.46
-total outstanding due of creditors other than micro enterprises and small enterprises	6,025.46	6,518.14
Other financial liabilities	842.10	1,011.97
Other current liabilities	1,099.72	518.58
Provisions	53.11	67.90
Current Tax Liabilities (net)	81.95	292.04
	15,980.27	16,619.97
TOTAL LIABILITIES	21,870.65	21,987.14
TOTAL EQUITY AND LIABILITIES	46,202.67	46,438.52

RB

Standalone Statement of Cash Flow

	Half Year ended 30 September 2025 Rs. in lakhs (Unaudited)	Half Year ended 30 September 2024 Rs. in lakhs (Unaudited)
Cash flow from operating activities		
Profit/ (loss) before tax	(205.48)	293.58
Depreciation and amortisation	961.81	988.94
Interest on lease deposits	(5.80)	(3.61)
(Gain)/ loss on sale of property, plant and equipment (net)	(17.26)	0.71
Unrealized foreign exchange gain (net)	(173.31)	(78.40)
Dividend income on investments	(0.75)	(0.75)
Interest income	(12.37)	(1.90)
Share based payments to employees	16.70	19.03
Loss allowance - trade receivables	51.52	-
Finance costs	646.29	574.36
Others	-	(5.12)
Operating profit before working capital changes	1,261.35	1,786.84
Movement in working capital :		
Increase in trade and other payables and provisions	(144.49)	(1,796.07)
(Increase) /decrease in inventories	(911.65)	1,333.71
Decrease in trade and other receivables	2,062.76	2,732.15
Net Cash generated from operations	2,267.97	4,056.63
Direct taxes paid (net of refunds)	(243.86)	(21.78)
Net cash from operating activities (A)	2,024.11	4,034.85
Cash flow from investing activities		
Purchases of property, plant and equipment and intangibles assets (Refer Note i)	(1,438.74)	(2,245.77)
Sale proceeds of property, plant and equipment	28.48	-
Investment in subsidiary	(291.75)	(107.98)
Deposits placed with bank (having original maturity of more than three months)	-	(25.50)
Maturity of bank deposits (having original maturity of more than three months)	-	17.50
Interest received	0.59	0.19
Dividend received	0.75	0.75
Net cash used in investing activities (B)	(1,700.67)	(2,360.81)
Cash flow from financing activities		
Proceeds from issue of equity share	7.76	-
Proceeds from long term borrowings	1,690.04	1,403.86
Repayment of long term borrowings	(1,001.86)	(690.05)
Repayment of short term borrowings (net)	(197.58)	(1,545.32)
Repayment of principal portion of lease obligations	(186.97)	(189.94)
Finance costs paid	(653.24)	(644.00)
Changes in unclaimed dividend bank balances	0.14	0.04
Changes in unclaimed dividend liabilities	(0.14)	(0.04)
Net cash used in financing activities (C)	(341.85)	(1,665.45)
Effects of exchange rate changes on cash and cash equivalents (D)	(0.25)	-
Net (decrease)/increase in cash and cash equivalents (A+B+C+D)	(18.66)	8.59
Opening cash and cash equivalents	36.36	17.35
Closing cash and cash equivalents	17.70	25.94
Components of cash and cash equivalents		
Cash on hand	3.40	16.26
Balances with banks in:		
- Current accounts	14.30	9.68
Total Cash and cash equivalents	17.70	25.94

Note (i) Includes capital work-in-progress, capital advance, payables for property, plant and equipment, intangibles assets and intangible assets under development.

Note (ii) The Statement of Cash Flow has been prepared under the indirect method as set out in Indian Accounting Standard (Ind AS 7) Statement of Cash flows.

